HDAC-IN-40

Cat. No.:	HY-146153
CAS No.:	2463198-51-6
Molecular Formula:	$C_{15}H_{22}N_2O_6$
Molecular Weight:	326.34
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (766.07 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0643 mL	15.3214 mL	30.6429 mL
	5 mM	0.6129 mL	3.0643 mL	6.1286 mL
	10 mM	0.3064 mL	1.5321 mL	3.0643 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with K_i values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects[1].

IC_{50} & Target

HDAC2 60 nM (Ki)	HDAC2 60 nM (Ki)	HDAC6 30 nM (Ki)	HDAC6 30 nM (Ki)
HDAC4 49200 μM (Ki)	HDAC8 5690 nM (Ki)		

In Vitro

HDAC-IN-40 (Compound 13d) shows antiproliferative activity against the cell line A2780 and Cal27 with IC_{50} values of 0.89 μM and 0.72 μM, respectively[1].

HDAC-IN-40 induces accumulation of acetyl α-tubulin in Cal27 and Cal27CisR[1].

HDAC-IN-40 enhances the Cisplatin-induced cytotoxicity via caspase-3/7 activation[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yodita Asfaha, et al. Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells. Bioorg Med Chem. 2020 Jan 1;28(1):115108.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA